Last reviewed · How we verify
xopenex
At a glance
| Generic name | xopenex |
|---|---|
| Also known as | levalbuterol |
| Sponsor | Phoenix Children's Hospital |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Approved indications
- Acute exacerbation of asthma
- Bronchospasm
- Bronchospasm Prevention
Common side effects
- Accidental injury
- Bronchitis
- Dizziness
- Pain
- Pharyngitis
- Rhinitis
- Vomiting
- Tremor
- Nervousness
- Cyst
- Flu syndrome
- Viral infection
Serious adverse events
- Anaphylaxis
- Angioedema
- Arrhythmias (including atrial fibrillation, supraventricular tachycardia, extrasystoles)
- Chest pain
- Metabolic acidosis
- Paradoxical bronchospasm
- Dyspnea
- Tachycardia
- Urticaria
- Rash
Key clinical trials
- A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (PHASE3)
- High Flow Nasal Cannula Rates in Pediatric Asthma (NA)
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis (PHASE1, PHASE2)
- A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (PHASE3)
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (PHASE4)
- A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (PHASE3)
- GRANITE: Airsupra Effectiveness in the Real World
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- xopenex CI brief — competitive landscape report
- xopenex updates RSS · CI watch RSS
- Phoenix Children's Hospital portfolio CI